Objective-In contrast to CD34, vascular endothelial-cadherin (VE-cadherin) is exclusively expressed on the late endothelial progenitor cells (EPC) whereas not on the early or myeloid EPC. Thus, VE-cadherin could be an ideal target surface molecule to capture circulating late EPC. In the present study, we evaluated whether anti-VE-cadherin antibody-coated stents (VE-cad stents) might accelerate endothelial recovery and reduce neointimal formation through the ability of capturing EPC. Methods and Results-The stainless steel stents were coated with rabbit polyclonal anti-human VE-cadherin antibodies and exposed to EPC for 30 minutes in vitro. The number of EPC that adhered to the surface of VE-cad stents was significantly higher than bare metal stents (BMS) in vitro, which was obliterated by pretreatment of VE-cad stent with soluble VE-cadherin proteins. We deployed VE-cad stents and BMS in the rabbit right and left iliac arteries, respectively. At 48 hours after stent deployment in vivo, CD-31-positive endothelial cells adhered to VE-cad stent significantly more than to BMS. At 3 days, scanning electron microscopy showed that over 90% surface of VE-cad stents was covered with endothelial cells, which was significantly different from BMS. 
D rug-eluting stents (DES) have shown dramatic efficacy in reducing neointimal hyperplasia through inhibition of smooth muscle cell (SMC) proliferation, leading to the remarkable increase of DES usage even for off-label indications. [1] [2] [3] However, stenting with DES interferes with the natural vascular healing process by preventing or delaying the formation of a functional endothelial monolayer over the stent. 4 The lack of a functional endothelial layer after vascular injury is a crucial factor for stent thrombosis as well as neointimal proliferation. 5, 6 To minimize the potential risk of stent thrombosis, newer DES with biocompatible or biodegradable polymers are developed and under clinical investigations. Nonetheless, the rapid restoration of a functional endothelium might be a more natural and plausible way to reduce stent thrombosis and restenosis after stent implantation.
Endothelial progenitor cells (EPC) can differentiate into mature endothelial cells, enhance re-endothelialization, and restore endothelial function after vascular injury, thus contribute to prevention of stent thrombosis and neointimal hyperplasia. [5] [6] [7] Therefore, therapies designed to mobilize EPC to the site of stent implantation and enhance vascular repair would be fascinating. Recently, EPC capture stent coated with monoclonal anti-human CD34 antibodies (Genous TM stent; OrbusNeich, Ft. Lauderdale, FL) was developed and considered to be a potential solution to the complications of DES. However, CD34 is not a specific or exclusive marker of EPC. CD34-positive cells are able to differentiate into various kinds of cells including inflammatory cells and vascular SMC. Actually, only a small portion of the CD34-positive cells are EPC. 8 -10 This problem, the lack of speci-ficity to capture EPC, may be one of the explanations of disappointing clinical results with EPC capture stents. 11, 12 EPC are heterogeneous cell populations and could be classified into at least 2 different types; early myeloid EPC versus late EPC or late outgrowth endothelial cells. 13 They have quite different characteristics especially in their morphology, proliferation rate, and survival. Early EPC are spindle-shaped, have a short lifespan, and enhance neovasculogenesis mainly by secreting angiogenic cytokines. On the other hand, late EPC with cobblestone appearance in culture show a long lifespan and contribute to neovasculogenesis by providing endothelial cells based on their high proliferation and differentiation potency.
VE-cadherin is a surface marker, which is exclusively expressed in the late EPC and endothelial cells, but not on the early EPC and other leukocytes. 13 Moreover, VE-cadherin is specifically expressed in adherent junctions of endothelial cells and exerts important functions such as intracellular signaling as well as cell-cell adhesion. 14 Therefore, we hypothesized that VE-cadherin is an ideal target surface marker for capturing EPC. In the present study, we investigated whether anti-VE-cadherin antibody coated stent (VEcad stent) would capture EPC specifically, accelerate re-endothelialization of the stent surface and reduce neointimal formation.
Methods
Expanded materials and methods are available in the Supplemental files, available online at http://atvb.ahajournals.org.
Cell Viability Assay of VE-Cadherin-Antibody Treated EPC
To assess the viability of EPC, we seeded 1ϫ10 4 human EPC to each well of 96-well plates, grown to near confluence level, and treated with anti-VE-cadherin antibodies. With 200 L of serum-free EBM-2 5% fetal bovine serum, VE-cadherin antibodies were treated at various doses (0 g/mL to 100 g/mL) with rabbit IgG to control the total amount of antibody between groups. Antibody-treated cells were incubated for 48 hours and morphological changes were observed with microscopy. Cell viability was assessed by cell proliferation reagent WST-1 assay, as instructed by the manufacturer.
Analysis of Antibody-Coated Surface
Scanning electron microscopy was performed to evaluate the surface integrity of stents. To confirm the status of antibody coating on stent surface, we performed immunofluorescent staining of anti-VEcadherin antibodies with anti-rabbit IgG antibodies (1:500, Alexa Fluor 555 Conjugate, Cell Signaling Technology, UK).
Capability of Capturing Late EPC
Late EPC grown to confluence were harvested and labeled with carboxyfluorescein succinimidyl ester (1:500, Sigma-Aldrich, St. Louis, MO) as instructed by the manufacturer. Suspensions of late EPC were prepared at the concentration of 10 5 cells/mL in the EGM-2MV. Stents were submerged into the separate tubes, filled with 2 mL of carboxyfluorescein succinimidyl ester-labeled late EPC suspensions. The EPC capturing capacity was assessed by counting the number of EPC firmly attached to the stent struts using a digital image-analysis system (Image-Pro Plus version 4.5, MediaCybernetics, Silver Spring, MD). We compared the EPC capturing capacity of BMS, polymer-coated stents, VE-cad stents, and VE-cad stents pretreated with soluble VE-cadherin proteins. To saturate the antigen-binding sites of anti-VE-cadherin antibodies, VE-cad stents were pretreated with soluble VE-cadherin proteins (AbFrontier, Seoul, Korea) of 100 g/mL overnight at 4°C before incubation with EPC.
Scanning Electron Microscopic Examination and Histomorphometric and Immunohistochemical Analysis
To evaluate re-endothelialization and neointimal hyperplasia after stenting, we implanted 12 BMS and 12 VE-cad stents in the right and left iliac arteries, respectively, in 12 rabbits (nϭ12, each stent). All stents were of the same size: 3 mm in diameter and 15 mm in length. Three days after stenting, 2 rabbits were harvested and their stents were dissected longitudinally to evaluate the luminal surface as en face, fixed in 2.5% glutaraldehyde and processed for scanning electron microscopy for evaluation of re-endothelialization.
At day 42, 10 rabbits were harvested and stented iliac arteries were removed and fixed in 10% buffered formalin with perfusion fixation. Great care needed to be taken when manipulating the stented vessels. They were embedded in resin and cut with tungsten blade. The degree of neointimal growth was analyzed in the sections stained with hematoxylin and eosin. Morphometric analysis was performed with a computerized digital image-analysis system (Image-Pro Plus version 4.5, MediaCybernetics, Silver Spring, MD). Cross-sectional images of stented rabbit iliac arteries were loaded onto Image-Pro Plus ® and neointimal areas are measured by the observer who was blinded to treatment. With the same samples, immunohistochemical staining was used to assess the infiltration of vascular smooth muscle or inflammatory cells to neointimal. We used antibodies against ␣-smooth muscle actin (Sigma) for smooth muscle cells and antibodies against RAM11 (Dako) for macrophages. We also used calponin (Abcam) as a smooth muscle or mural cell marker and proliferating cell nuclear antigen (PCNA) (Santa Cruz) as a proliferation marker.
Results

Expression of VE-Cadherin on the Surface of late EPC
First, we checked surface expression of VE-cadherin molecules on the late EPC. The late EPC monolayer grown to confluence showed a cobblestone-like appearance as we described previously. 15 Immunofluorescent staining of VEcadherin revealed that the VE-cadherin molecules are strongly expressed on the cell surface, especially at cell-cell contact junction ( Figure 1A ). FACS analysis showed that almost all the late EPC (99.1%) express VE-cadherin on their surface, however CD34 is detected on only 58.6% of late EPC ( Figure 1B ). These data suggest that VE-cadherin is a good target surface marker for capturing EPC.
Normal Growth of Late EPC Under the Treatment of Anti-VE-Cadherin Antibodies
Some antibodies such as anti-VEGFR2 were reported to reduce EPC viability after binding. 16 Thus, we exposed late EPC to a high concentration of anti-VE-cadherin antibodies and performed morphological analysis and WST-1 assay to investigate the effect of anti-VE-cadherin antibodies on viability and proliferation of late EPC.
After treatment with various concentrations of anti-VEcadherin antibodies for 48 hours, EPC were grown to confluence level and no definite morphological changes were observed ( Figure 2A ). Adherent cells were harvested and proliferative activities were assessed by WST-1 assay. After 1 hour of reaction, no significant differences were found between the antibody-treated groups and the control group ( Figure 2B ). Treatment of anti-VE-cadherin antibodies with high concentrations up to 100 g/mL did not affect the gross morphology or proliferation of EPC, alleviating the potential concerns about cell viability after antibody binding.
Surface of Antibody-Coated Stent and Capability to Capture Late EPC
Scanning electron microscopic examination of the VE-cad stents demonstrated smooth and complete surface integrity without any tear of polymers after full expansion of the stents ( Figure 3A ). Antibody coating status of the stent surfaces was confirmed by immunofluorescent staining with anti-rabbit IgG antibodies. As a result, VE-cad stents showed uniformly and densely coated surfaces, but BMS and polymer-coated stents did not emit any fluorescence as expected ( Figure 3B ). To determine the effect of VE-cad stent on EPC capture, suspended human late EPC were perfused from side to side in a cell-stock tube. The controls include BMS, polymer-coated stents, and VE-cad stents with antibodies occupied with soluble VE-cadherin proteins. After 30 minutes, the number of cells that were attached to the surface of BMS or polymer-coated stents were 15Ϯ3 or 9Ϯ2 per strut. In contrast, VE-cad stents captured 96Ϯ7 cells per strut on their surface, which was reversed by pretreatment with soluble VE-cadherin proteins (10Ϯ5 per strut) ( Figure 3C ). In conclusion, in vitro, VE-cad stents captured late EPC significantly more than BMS or polymer-coated stents did (PϽ0.001).
In Vivo Effects of VE-Cad Stent on Re-Endothelialization and Neointimal Hyperplasia After Stenting
Next, we investigated in vivo efficacy and relevance of VE-cad stents. Schematic diagram of study design and end points are illustrated in Figure 4A . At day 3 after stenting of VE-cad stents or BMS on the right and left iliac arteries in the same animal, we evaluated the re-endothelialization by scanning electron microscopy. Morphological analysis showed that over 90% of the surface of the VE-cad stent was covered with endothelium, whereas less than 10% of BMS surface was covered ( Figure 4B and 4C) .
After 3 days of stent implantation, the surfaces of the VE-cad stent were almost completely re-endothelialized as demonstrated above. Thus, to analyze the initial cells attaching on the VE-cad stent, we also harvested the stented rabbit iliac arteries at 48 hours after stent deployment, when the stent surface is not fully re-endothelialized. Confocal microscopic examination showed that many cells attached on the VE-cad stent and that most of them were stained with CD31/PECAM-1, which indicates that the initial captured cells are endothelial lineage. In contrast, on the BMS, a few cells were found and there was no CD31/PECAM-1 expression (Supplemental Figure IV) .
To evaluate the degree of neointimal hyperplasia, we harvested iliac arteries 6 weeks after stenting ( Figure 5A and 5B). In morphometric analysis, VE-cad stents showed a significantly reduced neointimal area than BMS did (neointimal area: 0.95Ϯ0.22 mm 2 versus 1.34Ϯ0.43 mm 2 , respectively, Pϭ0.02, nϭ10, Figure 5C ). Taken together, in vivo, VE-cad stents capture endothelial lineage cells, accelerate re-endothelialization, and reduce neointimal formation.
Immunohistochemical Analysis of the Neointimal Area
To address the potential concerns about nonspecific inflammation due to antibody coating, we performed immunohistochemical staining on neointimal area of the iliac arteries obtained at 6 weeks after stent implantation. The neointimal area of the iliac arteries stented with either VE-cad stent or BMS was composed predominantly of smooth muscle cells positive for smooth muscle actin ( Figure 5D and 5E) or calponin (Supplemental Figure VA) . Macrophage infiltration into the stented arteries, which was assessed by staining with RAM11, was limited and similar between the 2 stent groups ( Figure 5F and 5G). These data indicate that anti-VEcadherin antibodies as well as polymers coated on the stent struts do not cause any nonspecific inflammation, at least at the time point of 6 weeks after stent deployment.
Immunohistologic staining with PCNA ( Supplemental Figure VB) revealed that a considerable number of proliferating cells were found in the neointimal area of the both stent groups. The proportion of proliferating cells was much higher in the BMS group compared with the VE-cad stent group (Supplemental Figure VC and VD) . This result showed that the proliferative activity of the neointimal area at 6 weeks after stent deployment was still higher in BMS stented segment than VE-cad stented one. Taken together, the inhibition of infiltration or migration of SMC to intima due to rapid re-endothelialization in VE-cad stented segment resulted in the lower proliferative activity and smaller neointima than in BMS stented one.
To evaluate the effect of the polymer-coated stents on restenosis as well as inflammation, the iliac arteries stented with polymer-coated stents were compared with those stented with either VE-cad stents or BMS. The neointimal area stained with either smooth muscle actin or calponin was much larger in the polymer-coated stent group than in the VE-cad stent group, and no differences were found between the polymer-coated stent group and the BMS group (Supplemental Figure VIA) . Proliferative activity, represented by PCNA positive cells, was also much higher in the polymer-coated stent group than in the VE-cad stent group and was similar between the polymer-coated stent group and the BMS group, as expected (Supplemental Figure VIC and VID) . In addition, macrophage infiltration stained with RAM11, which stands for inflammatory response to the stent strut, was minimal and similar among the 3 stent groups (Supplemental Figure VIB) . These results showed that inhibition of neointimal proliferation by rapid re-endothelialization was caused not by polymers but by VE-cadherin antibodies and that polymer itself did not cause any further nonspecific inflammation.
Discussion
In the present study, we developed a new antibody-coated stent using rabbit polyclonal anti-human VE-cadherin antibody and unique coating technique. 17 We demonstrate that (1) in vitro, anti-VE-cadherin antibody did not affect the viability or proliferation of late EPC, and VE-cadherin antibodycoated stents (VE-cad stents) captured late EPC significantly more than BMS or polymer-coated stents did; (2) in vivo, VE-cad stents accelerated re-endothelialization and showed almost complete coverage of the luminal surfaces of the stent within 72 hours after stent deployment in the rabbit iliac artery; and (3) VE-cad stents reduced neointimal hyperplasia compared with BMS at 42 days after stent implantation in the same rabbit model.
EPC and Vascular Injury
Endothelial denudation is considered to be a primary event after balloon angioplasty and stent deployment. The lack of functional endothelium and subsequent inflammatory cell . In vivo confirmation of the efficacy of vascular endothelial-cadherin (VE-cad) stent after implantation to rabbit iliac artery. A, Schematic diagram of animal experiment. B, C, Rapid re-endothelialization on VE-cad stents compared with bare metal stents. Scanning electron microscopy at 3 days showed that over 90% of stent surfaces were covered after VE-cad stents deployment (shown in B), while less than 10% of stent surfaces were covered with endothelial cells after bare metal stents deployment (shown in C).
infiltration into the injured artery cause smooth muscle cell migration and proliferation, which results in neointimal hyperplasia. 18 In particular, coronary atherosclerotic lesions are rich in cytokines and growth factors, thus more prone to restenosis after stent insertion. DES have shown excellent efficacy in preventing restenosis and have mostly replaced BMS in real-world practice. However, the delayed re-endothelialization owing to antiproliferative drugs and hypersensitivity reaction to stent polymers increased the risk of late and very late stent thrombosis in patients implanted with DES. 19, 20 To overcome this detrimental side effect, a number of attempts have been made to develop new coronary stents with improved technologies.
It is well known that bone marrow-derived EPC contribute to the repair of the endothelium after vascular injury. 21 For instance, the number of circulating EPC is significantly increased after myocardial infarction. 22 Infusion of EPC accelerates re-endothelialization and effectively prevents smooth muscle cell proliferation and neointima formation after vascular injury. 5, 6 Once an endothelial layer forms, the chance of blood clot formation may also decrease. Therefore, promotion of vascular healing by rapid re-endothelialization, eg, by EPC capture stents, would be a more natural and safer approach.
CD34, Not Optimal Target Surface Molecule for Capturing EPC
Several groups have developed EPC capture stents or grafts using antibodies, peptides or even aptamers. [23] [24] [25] Representative EPC capture stent is Genous TM stent (OrbusNeich, Ft. Lauderdale, FL), which uses murine monoclonal antibodies against human epitopes of CD34. This stent is evaluated through several single-arm clinical studies and shown to be safe and feasible for the treatment of coronary artery disease. 26 -28 However, the disappointing results were published recently in the randomized controlled trials. In the TRIAS-HR study where they enrolled patients with lesions carrying a high risk of restenosis, the Genous stent showed a trend of higher rates of target vessel failure compared with the paclitaxel-eluting stent, mainly because of more target vessel revascularization. 12 In the GENIUS-STEMI trial in patients with ST-elevation myocardial infarction, the rate of stent thrombosis at 6 months was 6% in the Genous stent group whereas 0% in BMS group, which raises doubts about the promise of the Genous stent in terms of safety. 11 The most concerning point is that CD34-positive progenitor cells can differentiate into various cell types, including vascular SMC and monocytes and macrophages. 10 Moreover, only part of the CD34-positive cells is EPC whereas CD34-negative mesenchymal cells can also differentiate into endothelial cells. 8, 9, 29, 30 Such limitations in CD34 may be reasonable mechanisms for the limited efficacy of the Genous stent in the clinical trials.
VE-Cadherin as a Target Surface Molecule for Capturing EPC
As we described before, late EPC have longer lifespans and higher proliferation potencies compared with early myeloid EPC. Late EPC are actual building blocks for re-endothelialization whereas myeloid EPC send growth signals to late ones. 13 Because late EPC and endothelial cells express VE-cadherin abundantly on their surfaces, we chose VEcadherin as a target surface molecule to attach circulating endothelial cells and EPC (exclusively late EPC). Though CD34 molecule is one of the representative markers of EPC, it is relatively nonspecific to select true EPC. Our results of FACS analysis showed that CD34 molecule was detected in only about 60% of late EPC because its expression weakens as monocytes are fully committed to late EPC. 21 However, VE-cadherin was expressed on almost all the late EPC.
VE-cadherin regulates diverse cellular processes such as cell proliferation and apoptosis, and modulates the functions . By digital image-analysis system, neointimal area of VE-cad stents was significantly smaller than that of BMS (C). D-G, Absence of inflammation at 42 days after VE-cad stent implantation. Neointimal area was mainly filled with smooth muscle cells positive for ␣-smooth muscle actin (SMA) in the iliac artery implanted with either VE-cad stents (D) or BMS (E). In contrast, macrophage infiltration which was assessed by staining with RAM11, was limited and similar between the two stent groups (F, G).
of VEGF receptor, in addition to its adhesive functions. 31 Thus, anti-VE-cadherin antibodies may affect the viability or proliferation of late EPC. In order to exclude such unexpected side effects of antibody, we performed in vitro experiments and found that treatment of anti-VE-cadherin antibodies with high concentration up to 100 g/mL did not affect the gross morphology or proliferation of EPC.
Rapid Re-Endothelialization and Reduced Neointimal Growth
We developed a new EPC capture stent and tested its efficacy through in vitro and in vivo animal test. Vascular SMC migration and mobilization of smooth muscle progenitor cells to the site of vascular injury starts within the first 24 hours after the arterial denudation. 32 Therefore, complete re-endothelialization within a few days is of importance not only for the prevention of stent thrombosis but also for the inhibition of neointimal growth. In this study, over 90% of VE-cadherin stent struts was covered with endothelial cell-like cells at 72 hours after stent deployment at rabbit iliac artery. Rapid re-endothelialization of VE-cad stent was translated into the reduced neointimal hyperplasia at 6 weeks after stent implantation.
Antibody Coating Technique
There are number of advantages in our antibody coating technique applied to our stent when comparing with other types of antibody coated stents or drug eluting stents. First, surfaces of stainless steel are modified by electropolishing and silanization to attach polymers. Silanization process itself is a kind of coating of a thin silicone film over the stent and allows a very firm and stable polymer coating, which is fundamentally different from the polymer coating of DES. Moreover, biocompatibility and hydrophilicity are both achieved by using polyethylene glycol as polymers. 33 Taken together, those characteristics might lead to less thrombotic stent surfaces and less inflammation. Finally, antibodies are covalently bonded to the polymers and are not diluted by blood flow, leading to strong ability to capture VE-cadherinpositive cells.
Study Limitations
There are several limitations to this study. First, we compared VE-cad stent only with BMS. To better evaluate the clinical implications of VE-cad stents, it is necessary to conduct a head-to-head comparison between VE-cad stents and anti-CD34 antibody-coated stents. Second, this study is limited to observations in experimental animal models, thus its clinical relevance to human beings is uncertain. Finally, technical improvements, such as sterilization procedure and the use of monoclonal antibodies instead of polyclonal ones, should precede the clinical application of VE-cad stent.
Conclusion
We have tried to develop a novel EPC capture stent with improved selectivity and efficacy by targeting VE-cadherin. Anti-VE-cadherin antibody-coated stent could capture circulating late EPC and endothelial cells more effectively and specifically in vitro. Its capability of rapid re-endothelialization and restenosis prevention was proved in animal experiments.
